Specific Targeting of Tumor Endothelial Cells by a Shiga-like Toxin-vascular Endothelial Growth Factor Fusion Protein As a Novel Treatment Strategy for Pancreatic Cancer

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2010 Oct 8

PMID 20927318

Citations 13

Authors

Birgit Hotz

Marina V Backer

Joseph M Backer

Heinz-J Buhr

Hubert G Hotz

Affiliations

Soon will be listed here.

Abstract

Purpose: Tumor endothelial cells express vascular endothelial growth factor receptor 2 (VEGFR-2). VEGF can direct toxins to tumor vessels through VEGFR-2 for antiangiogenic therapy. This study aimed to selectively damage the VEGFR-2-overexpressing vasculature of pancreatic cancer by SLT-VEGF fusion protein comprising VEGF and the A subunit of Shiga-like toxin which inhibits protein synthesis of cells with high VEGFR-2 expression.

Experimental Design: Expression of VEGF and VEGF receptors was evaluated in human pancreatic cancer cells (AsPC-1, HPAF-2) and in normal human endothelial cells (HUVEC) by reverse transcription-polymerase chain reaction. Cells were treated with SLT-VEGF (0.1-10 nM), and cell viability, proliferation, and endothelial tube formation were assessed. Orthotopic pancreatic cancer (AsPC-1, HPAF-2) was induced in nude mice. Animals were treated with SLT-VEGF fusion protein alone or in combination with gemcitabine. Treatment began 3 days or 6 weeks after tumor induction. Primary tumor volume and dissemination were determined after 14 weeks. Microvessel density and expression of VEGF and VEGF receptors were analyzed by immunohistochemistry.

Results: SLT-VEGF did not influence proliferation of pancreatic cancer cells; HUVECs (low-level VEGFR-2) reduced their proliferation rate and tube formation but not their viability. SLT-VEGF fusion protein reduced tumor growth and dissemination, increasing 14-week survival (AsPC-1, up to 75%; HPAF-2, up to 83%). Results of gemcitabine were comparable with SLT-VEGF monotherapy. Combination partly increased the therapeutic effects in comparison to the respective monotherapies. Microvessel density was reduced in all groups. Intratumoral VEGFR-2 expression was found in endothelial but not in tumor cells.

Conclusions: SLT-VEGF is toxic for tumor vasculature rather than for normal endothelial or pancreatic cancer cells. SLT-VEGF treatment in combination with gemcitabine may provide a novel approach for pancreatic cancer.

Citing Articles

An Overview of Selected Bacterial Infections in Cancer, Their Virulence Factors, and Some Aspects of Infection Management.

Ray A, Moore T, Pandit R, Burke A, Borsch D Biology (Basel). 2023; 12(7).

PMID: 37508393 PMC: 10376897. DOI: 10.3390/biology12070963.

A-NGR fusion protein induces apoptosis in human cancer cells.

Mohammadi-Farsani A, Habibi-Roudkenar M, Golkar M, Shokrgozar M, Jahanian-Najafabadi A, Khanahmad H EXCLI J. 2018; 17:590-597.

PMID: 30108463 PMC: 6088213. DOI: 10.17179/excli2018-1120.

Tetraspecific ligand for tumor-targeted delivery of nanomaterials.

Kim D, Friedman A, Liu R Biomaterials. 2014; 35(23):6026-36.

PMID: 24786763 PMC: 4205110. DOI: 10.1016/j.biomaterials.2014.04.015.

Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.

Jiang W, Lu X, Shang B, Fu Y, Zhang S, Zhou D BMC Cancer. 2013; 13:479.

PMID: 24128285 PMC: 4016579. DOI: 10.1186/1471-2407-13-479.

The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.

Mohamedali K, Cao Y, Cheung L, Hittelman W, Rosenblum M Mol Cancer Ther. 2013; 12(10):2055-66.

PMID: 23858102 PMC: 3921020. DOI: 10.1158/1535-7163.MCT-13-0165.

References

Hotz H, Reber H, Hotz B, Foitzik T, Buhr H, Cortina G . An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats. Pancreas. 2001; 22(2):113-21. DOI: 10.1097/00006676-200103000-00002. View

Weidner N . Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol. 1998; 184(2):119-22. DOI: 10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D. View

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13(1):9-22. View

Philip P . Targeting angiogenesis in pancreatic cancer. Lancet. 2008; 371(9630):2062-4. DOI: 10.1016/S0140-6736(08)60770-9. View

Backer M, Gaynutdinov T, Patel V, Bandyopadhyaya A, Thirumamagal B, Tjarks W . Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther. 2005; 4(9):1423-9. DOI: 10.1158/1535-7163.MCT-05-0161. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M . Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 1999; 85(1):27-34. DOI: 10.1002/(sici)1097-0215(20000101)85:1<27::aid-ijc5>3.0.co;2-8. View

Bergers G, Hanahan D . Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603. PMC: 2874834. DOI: 10.1038/nrc2442. View

Philip P . Targeted therapies for pancreatic cancer. Gastrointest Cancer Res. 2009; 2(4 Suppl):S16-9. PMC: 2661543. View

10.

Hotz H, Gill P, Masood R, Hotz B, Buhr H, Foitzik T . Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg. 2002; 6(2):159-66; discussion 166. DOI: 10.1016/s1091-255x(01)00040-3. View

11.

Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K . Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000; 60(2):203-12. View

12.

Veenendaal L, Jin H, Ran S, Cheung L, Navone N, Marks J . In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A. 2002; 99(12):7866-71. PMC: 122986. DOI: 10.1073/pnas.122157899. View

13.

Zhang Z, Neiva K, Lingen M, Ellis L, Nor J . VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2009; 17(3):499-512. PMC: 2822115. DOI: 10.1038/cdd.2009.152. View

14.

Kuehn R, Lelkes P, Bloechle C, Niendorf A, Izbicki J . Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas. 1999; 18(1):96-103. DOI: 10.1097/00006676-199901000-00012. View

15.

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

16.

Ramakrishnan S, Olson T, Bautch V, Mohanraj D . Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 1996; 56(6):1324-30. View

17.

von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schirner M . De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology. 2000; 119(5):1358-72. DOI: 10.1053/gast.2000.19578. View

18.

Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M . Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000; 60(17):4819-24. View

19.

Wedge S, Ogilvie D, Dukes M, Kendrew J, Curwen J, Hennequin L . ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000; 60(4):970-5. View

20.

Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A . Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999; 79(9-10):1553-63. PMC: 2362700. DOI: 10.1038/sj.bjc.6690248. View